View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Market Data
July 11, 2017updated 26 Oct 2017 12:40pm

Declining trend in Japanese clinical trials

GlobalData has analysed clinical trials initiated in Japan over the last five years according to their phases. This study captured records of 8,615 clinical trials across all diseases and phases that had a start date 1 January, 2012, and 31 December, 2016.

By GlobalData Healthcare

GlobalData has analysed clinical trials initiated in Japan over the last five years according to their phases. This study captured records of 8,615 clinical trials across all diseases and phases that had a start date 1 January, 2012, and 31 December, 2016.

The total number of new clinical trials was 1,950 in 2012, decreasing to 1,516 in 2016. The most prominent decrease, at 16%, occurred in 2014.

Phase II Most Prominent

A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively. Overall, Phase II trials outnumbered all other trials by contributing between 55% and 62% across the period. The share of Phase I trials started at 11% in 2012 and decreased to 10% by 2016, as shown in Figure 1. Phase III trials’ contribution remained flat at 16% across the five-year period, whereas Phase IV trials increased in share from 11% to 16% in the first and last year, respectively.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU